SOMA Research

What Is KPV? A Research Guide to the Alpha-MSH Tripeptide

KPV is a tripeptide — three amino acids, lysine, proline and valine — taken from the tail end of a much larger hormone. It is the smallest peptide in the SOMA catalogue by residue count, and like Semax it exists because someone asked whether the signalling properties of a hormone fragment could be separated from the hormone’s endocrine activity. This guide covers the structure, where it comes from, what the published literature examines, and how to handle it.

SOMA Research supplies KPV for laboratory research use only. It is not a drug, supplement, food or cosmetic, is not approved by the FDA for any use, and is not intended for human or veterinary consumption.

What KPV is

  • Sequence: Lys-Pro-Val (KPV)
  • CAS number: 67727-97-3
  • Molecular formula: C16H30N4O4
  • Molecular weight: approximately 342.4 g/mol
  • Length: 3 amino acids
  • Appearance: white lyophilised powder

Where the sequence comes from

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, α-MSH, a 13-residue peptide. Numbered along that hormone, KPV is residues 11–13 — the last three before the C-terminus.

The part of α-MSH responsible for melanocortin receptor binding, and therefore for its pigmentation-related activity, lies in the middle of the sequence around the His-Phe-Arg-Trp core. KPV does not contain it. That is the entire point of the fragment: it was isolated to study properties attributed to α-MSH without the receptor activity that defines the hormone.

This is worth connecting to another compound in the catalogue. α-MSH and ACTH are both derived from the same precursor protein, pro-opiomelanocortin, and share sequence. Semax is built on ACTH(4–7) — the Met-Glu-His-Phe stretch. KPV is α-MSH(11–13). Two compounds, two fragments of the same precursor family, each chosen to isolate activity away from the hormonal core. A researcher holding both is holding two instances of the same design strategy applied at opposite ends of a related sequence.

What the published research examines

The KPV literature is preclinical — cell culture and rodent models. The recurring threads:

  • Inflammatory signalling in cell models. A substantial part of the work examines NF-κB pathway activity in cultured cells, which is the mechanistic thread most often cited.
  • Epithelial uptake. Studies on transport into intestinal epithelial cells via the PepT1 di/tripeptide transporter — relevant because PepT1 handles small peptides specifically, and a tripeptide is the right size for it where a larger peptide is not.
  • Colitis models. Rodent models of intestinal inflammation, following from the epithelial transport work.
  • Comparisons with full-length α-MSH. Work asking whether the fragment reproduces properties of the parent hormone, which is the question the fragment exists to answer.

No approved human indication exists and there is no completed body of peer-reviewed human efficacy data. Commercial claims about human outcomes are not supported by this evidence base.

Why three residues changes the analytics

A tripeptide is a different analytical problem from a 44-residue peptide, and in some ways a harder one to read on a certificate.

Synthesis is clean, so purity figures run high. Three couplings produce far fewer deletion sequences than forty-four. A high HPLC purity number on a tripeptide is therefore less informative than the same number on a long peptide — it is closer to the expected floor than to a distinguishing achievement. The number still matters; it just discriminates less between suppliers.

Retention is short. KPV is small and polar, so on a standard reversed-phase gradient it elutes early, close to the void volume where injection artefacts and unretained salts also appear. A method that does not resolve that region well can report a clean-looking peak that is partly not the peptide. If a CoA for a very short peptide shows the main peak eluting almost immediately, the method is worth more scrutiny than the percentage.

Mass confirmation is unambiguous. At approximately 342.4 g/mol the molecule is small enough that electrospray gives a simple, singly charged signal rather than the multiply charged envelope a large peptide produces. Identity confirmation is correspondingly clean.

Counter-ion is proportionally larger. This is the one that bites. Acetate contributes roughly 60 g/mol. Against a 5,000 g/mol peptide that is about 1% of the weighed mass; against 342 g/mol it is far more. The gap between nominal mass and actual peptide content is therefore much wider for a tripeptide, and using label weight as peptide weight introduces a correspondingly larger error. Read the peptide-content figure, which is a different number from HPLC purity — our Certificate of Analysis guide explains where each appears.

Every SOMA lot is tested by third-party laboratories using HPLC and mass spectrometry, with measured figures published per lot in our CoA library.

Handling and storage

  • Lyophilised powder: -20°C, protected from light.
  • Before opening: bring the vial to room temperature, so atmospheric moisture does not condense into the powder.
  • Reconstituted stock: 2–8°C, aliquoted, used within approximately 30 days.
  • Small peptides are easy to lose. A three-residue peptide dissolves readily, which is convenient, but at low working concentrations adsorption to tube walls and pipette tips is a real source of loss. Low-binding plasticware is worth using for dilute solutions.
  • Avoid freeze-thaw cycling of reconstituted stock.

The general procedure and the concentration arithmetic are in our reconstitution guide.

Research use only

Research-grade KPV is supplied for laboratory use by qualified researchers and institutions. It is not manufactured to pharmaceutical standards, has not been approved by the FDA for any use, and must not be used in or on humans or animals. Nothing in this guide is medical advice or a representation that the compound is safe or effective for any purpose.